RUNX1 and acute myeloid leukemia: Recently, elegant studies in mouse models have shown that BET inhibition specifically targets recurrent genetic lesions in AML including IDH2 and FLT3-ITD mutations, complete or interstitial chromosome 7 deletion, and inv(3)/t(3;3) associated with aberrant EVI1 expression [32], [33], [34].